SCHEMBL10261916

SCHEMBL10261916

Cc1cn(C2COC2)c2ncnc(N)c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 2/20 0.55
RET P07949 5/20 0.55
RIPK2 O43353 4/20 0.48
SRC P12931 7/20 0.46
ABL1 P00519 6/20 0.46
LCK P06239 3/20 0.46
FYN P06241 2/20 0.46
FLT1 P17948 2/20 0.46
LTK P29376 2/20 0.46
KDR P35968 2/20 0.46
MAP2K2 P36507 2/20 0.46
FLT3 P36888 2/20 0.46
CDK8 P49336 2/20 0.46
MAP2K1 Q02750 2/20 0.46
ACVR1 Q04771 2/20 0.46
TNK2 Q07912 2/20 0.46
NTRK3 Q16288 2/20 0.46
NTRK2 Q16620 2/20 0.46
AURKB Q96GD4 2/20 0.46
DAPK3 O43293 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24072104 0.86 RIPK2 (0.61) ADKRETRIPK2SRCABL1
SCHEMBL19264162 0.84 SRC (0.61) ADKRETRIPK2SRCABL1
SCHEMBL14643106 0.82 ADK (0.52) ADKRETRIPK2SRCABL1
SCHEMBL19563041 0.82 ADK (0.55) ADKRETRIPK2SRCABL1
SCHEMBL14643787 0.82 ADK (0.52) ADKRETRIPK2SRCABL1
SCHEMBL23966749 0.82 ADK (0.61) ADKRETSRCABL1LCK
SCHEMBL870154 0.82 METTL3 (0.58) ADKRETSRCABL1LCK
SCHEMBL20351760 0.82 ADK (0.55) ADKRETRIPK2SRCABL1
SCHEMBL6925160 0.82 RET (0.52) RETRIPK2SRCABL1LCK
SCHEMBL14644244 0.80 RIPK2 (0.52) ADKRETRIPK2SRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 WO disclosed
WO-2021226547-A2 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. (US) 2021-11-11 WO disclosed
US-20130018038-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2013-01-17 US disclosed
US-20120077828-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018038-A1 CHEMICAL COMPOUNDS BRCA1, IRS1, IGF1R ADK 1509/4885RET 2772/4885RIPK2 503/4885
US-20120077828-A1 CHEMICAL COMPOUNDS BRCA1, IRS1, IGF1R ADK 1509/4885RET 2772/4885RIPK2 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.